書籍詳細

1 ◎ トリグリセライド、HDLとコレステロール

P.21 掲載の参考文献

• 1) 山本 章ほか:高脂血症における血清燐脂質とその脂肪酸組成について. 臨床病理 23:13-19, 1974

• 2) Scott J:Regulation of the biosynthesis of apolipoprotein B100 and apolipoprotein B48. Curr opin Lipidol 1:96-103, 1990

• 3) Boren J et al:Studies on the assembly of apolipoprotein B-100 and B-48-containing very low density lipoproteins in McA-RH 7777cells. J Biol Chem 269:25879-25888, 1994

• 4) Young SG:Recent progress in understanding apolipoprotein B. Circulation 82:1574-1594, 1990
  pubmed

• 5) 山本 章:血漿トリグリセライド代謝におけるリポ蛋白リパーゼと肝性トリグリセライドリパーゼの役割. 動脈硬化 24:147-153, 1996

• 6) Ito Y et al:Hypemiglyceridemia as a result of human apo C-III gene expression in transgenic mice. Science 249:790-793, 1990
  pubmed

• 7) Maeda N et al:Targeted disruption of the apolipoprotein C-III gene in mice resuts in hypotriglyceridemia and protection from the postprandial hypertriglyceridaemia. J Biol Chem 269:23610-23616, 1994

• 8) Talmud P, Humphries SE:Apolipoprotein C-III gene variation and dislipidaemia. Curr opin Lipido 18:154-158, 1997

• 9) Surguchov AP et al:Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscl Thromb Vascul Biol 16:941-947, 1996

• 10) Huuskonen J and Ehnholm C:Phospholipid transfer protein in lipid metabolism. Curr opin Lipidol 11:285-289, 2000
  pubmed

• 11) Hitsumoto T et al:Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis 153:391-396, 2000
  pubmed

• 12) Drayna D et al:Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 327:632-634, 1987
  pubmed

• 13) Ohnishi T et al:Rapid purification of humam plasma lipid transfer proteins. J Lipid Res 31:397-406, 1990

• 14) 池田康行ほか:高トリグリセライド血症と small dense LDL. Ther Res 19:3455-3465, 1998
  Medical*Online

• 15) Williams DL et al:Scavenger receptor B1 and cholesterol trafficking. Curr opin Lipidol 10:329-339, 1999

• 16) Trigatti B et al:The role of the high-density lipoprotein receptor SR-B1 in cholesterol. Metabolism 11:123-131, 2000

• 17) Ji Y et al:Hepatic scavenger receptor B1 promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem 274:33398-33402, 1999

• 18) Cohen J et al:Hepatic lipase:New insights from genetic and metabolic studies. Curr opin Lipidol 10:259-267, 1999
  pubmed

• 19) Nie L, Wang J, Clark LT et al:Body mass index and hepatic lipase gene(LIPC) polymophism jointly influence postheparin plasma hepatic lipase activity. J Lipid Res 39:1127-1130, 1998

• 20) Tan KCB et al:Effect of the-514 polymorphism in the hepatic lipase gene on postheparin plasma hepatic lipase activity in Chinese subjects. (abstract ThP29:W30, XII th Int Symp Atheroscl) Atherosclerosis 151:270, 2000

• 21) Ashley DT et al:Factors influencing the ability of high-density lipoproteins to inhibit the expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscl Thromb Vascul Biol 18:1450-1455, 1998

2 ◎ 見直されるトリグセライド、HDLの意義

P.27 掲載の参考文献

• 1) Fruchart JC, Brewer HB Jr, Leitersdorf E:Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 81:912-917, 1998

• 2) Shimada M, Ishibashi S, Inaba T et al:Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc Natl Acad Sci USA 93:7242-7246, 1996
  pubmed

• 3) Krauss RM:Triglyceride and atherogenic lipoproteins:rationale for lipid management. Am JMed 105(1A):58S-62S, 1998

• 4) Havel RJ:Postprandial lipid metabolism:an overview. Proc Nutr Soc 56:659-666, 1997
  pubmed

• 5) Schmitz G, Langmann T:Structure, function and regulation of the ABC1 gene product. Curropin Lipidol 12:129-140, 2001
  pubmed

• 6) Reaven GM:Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
  pubmed

• 7) Yamada N, Yoshinaga H, Sakurai N et al:Increased risk factors for coronary artery disease in Japanese subjects with hyperinsulinemia or glucose intolerance. Diabetes Care 17:107, 1994
  pubmed

3 ◎ リスクファクターとしてのトリグリセライド

P.42 掲載の参考文献

• 1) Elkeles RS, Diamond JR, Poulter C et al:Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate:the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 21:641-648, 1998

• 2) Hokanson JE, Austin MA:Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level:a meta-analysis of population-based prospective studies. J Cardiovascular Risk 3:213-219, 1996

• 3) Haim M, Benderly M, Brunner et al:Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease:the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 100 (5):475-482, 1999
  pubmed

• 4) Stamler J, Wentwonrth, Neaton JD:Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA 256:2823-2828, 1986
  pubmed

• 5) 中村治雄:原発性高脂血症の疫学. 高脂血症-治療と病態(垂井清一郎, 松沢佑次 編), 厚生省特定疾患「原発性高脂血症」調査研究班事務局, 1998, p44-55

• 6) Castelli WP, Garrison RJ, Willson PW et al:Incidence of coronary heart disease and lipoprotein cholesterol level. The Framingham Study. JAMA 28:2835-2838, 1986

• 7) Scandinavian Simvastatin Survival Study Group:Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383, 1994

• 8) Sacks MF, Pfeffer MA, MoyeLA et al:The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996

• 9) Shepherd J, Cobbe SM, Ford I et al:Prevention of coronary heart disease with pravastatin in ischemic disease (LIPID) Study Group. N Engl J Med 333:1301-1307, 1995

• 10) Downs JR, Clearfield M, Weis S et al:Primary prevention of coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS. Airforce/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622, 1998

• 11) Yoshino G, Hirano T, Maeda E et al:Effect of long-term exogenous hyperinsulinemia and fructose or glucose supplementation on triglyceride turnover in rats. Atherosclerosis 129:33-39, 1997
  pubmed

• 12) Reaven GM:Banting Lecture 1998. Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988

• 13) Kaplan NM:The deadly quartet, upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intem Med 149:1514-1520, 1989

• 14) DeFronzo RA, Ferrannini E:Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
  pubmed

• 15) Matsuzawa Y:Pathophysiology and molecular mechanisms of visceral fat syndrome:the Japanese experience. Diab Metab Rev 13:3-13, 1997

• 16) Krauss RM:Low-density lipoprotein subclass and risk of coronary disease. Curr Opin Lipidol 4:248-252, 1991

• 17) Kasama T, Yoshino G, Iwatani I et al:Increased cholesterol concentrations in intermediate density lipoprotein fraction of nommolipidemic non-insulin dependent diabetics. Atherosclerosis 63:263-266, 1987
  pubmed

• 18) 坂上太郎, 平野 勉, 芳野 原ほか:レムナント-リポ蛋白におよぼす糖尿病性腎症の影響. 糖尿病 42:439-446, 1999

• 19) Iwai M, Yoshino G, Matsushita M et al:Abnormal lipoprotein composition in normolipidemic diabetic patients. Diabetes Care 13:792-796, 1990
  pubmed

• 20) Hirano T, Oi K, Sakai S et al:High Prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. Atherosclerosis 123:57-72, 1996

• 21) Nakajima K, Saito T, Tamura A et al:A new assay method for the quantification of cholesterol in remnant-like particles in human serum using monoclonal anti-apo B100 and anti-apo A-1 immunoaffinity mixed gels. Clin Chim Acta 223:53-71, 1993

• 22) McNamara JR, Shah PK, Nakajima K et al:Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women:results from the Framingham Heart Study. Atherosclerosis 154:229-236, 2001
  pubmed

• 23) Kazumi T, Kawaguchi A, Hayakawa M et al:Remnant lipoprotein cholesterol (RLP-C) is part of insulin resistance syndrome. Diabetes 47 (Supple. 1):A32, 1998

• 24) Sakata K, Miho N, Shirotani M et al:Remnant-like particle cholesterol is a major risk factor for myocardial infarction in vasospastic angina with nearly normal coronary artery. Atherosclerosis 136:225-231, 1998
  pubmed

• 25) Inoue T, Saniabadi AR, Matsunaga R et al:Impaired endothelium-dependent acetylcholine-induced coronary artery relaxation in patients with high serum remnant lipoprotein particles. Atherosclerosis 139:363-367, 1998
  pubmed

• 26) Devaraji S, Vega G, Lanse R et al:Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. Am J Med 104:445-450, 1998
  pubmed

• 27) Marcoux C, Tremblog M, Frederich A et al:Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects. Atherosclerosis 139:161-171, 1998

• 28) Syvanne M, Hilden H, Taskinen MR:Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease. J Lipid Res 35:15-26, 1994

• 29) Feingold KR, Grunfeld C, Pang M et al:LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 12:1496-1502, 1992
  pubmed

• 30) Coresh J, Kwiterorich PO, Smith HH et al:Association of plasma triglyceride concentration and LDL particle diameter, density and chemical composition with premature coronary artery disease in men and women/J Lipid Res 34:1687-1693, 1993

• 31) Galeano NF, Milne R, Marcel YL et al:Apolipoprotein-B structure and receptor recognition of triglyceride-rich low density lipoprotein(LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem 269:511-519, 1994
  pubmed

• 32) Chen GC, Liu W, uchateau P et al:Conformational differences in human apolipoprotein B-100 among subspecies of low density lipoproteins(LDL). Association of altered proteolytic accessibility with decreased receptor binding of LDL subspecies from hypertriglyceridemic subjects. J Biol Chem 269:29121-29128, 1994
  pubmed

• 33) Galeano NF, AL-Haideri M, Keyserman F et al:Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites:a potential mechanism for increased atherogenicity. J Lipid Res 39:1263-1273, 1998
  pubmed

• 34) Koba S, Hirano T:Small, dense low-density lipoprotein in Japanese men with coronary artery disease. Am Int Med 132:762, 2000

• 35) Kazumi T, Kawaguchi A, Hozumi T et al:Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. Atherosclerosis 142:113-119, 1999
  pubmed

• 36) Yoshino G, Kazumi T:Dyslipidemia in diabetes and obesity. Proceedings of the 2nd WHO Symposium on Health Issues for the 21st Century:Nutrition and Quality of life, Kobe 1993 (Pietinen et al ed) , WHO Printing office, Geneva, 1996, pp 169-180

• 37) Karhapaa P, Malkki M, Laakso M:Isolated low HDL cholesteroL An insulin-resistant state. Diabetes 43:411-417, 1994
  pubmed

4 ◎ multiple risk factor症候群

P.53 掲載の参考文献

• 1) Reaven GM:Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
  pubmed

• 2) Kaplan NM:The deadly quartet:upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149:1514-1520, 1989
  pubmed

• 3) DeFronzo RA, Ferrannini E:Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173, 1991
  pubmed

• 4) Nakamura T, Tokunaga K, Shimomura I et al:Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107:239, 1994

• 5) Kameda K, Matsuzawa Y, Kubo M et al:Increased Frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan. Atherosclerosis 51:241-249, 1984
  pubmed

• 6) 垂井清一郎:日本人における高脂血症とその合併症. 動脈硬化 18:1-16, 1990

• 7) 板倉弘重ほか(J-LIT研究会):J-LIT有効性・安全性, 一次予防, 二次予防, 第33回日本動脈硬化学会総会で発表

• 8) Nakamura T, Tsubono Y, Kameda-Takemura K et al:Magnitude of sustained multiple riskfactors for ischemic heart disease in Japanese employees-a case-control study-. Jpn Circ J 65:11-17, 2001

• 9) Kobayashi H, Nakamura T, Miyaoka K et al:Visceral fat accumulation contributes to insulin resistance, small-sized low-density lipoprotein, and progression of coronary artery disease in middle-aged non-obese Japanese men, Jpn Circ J 65:193-199, 2001
  pubmed

• 10) Kuriyama H, Yamashita S, Shimomura I et al:Enhanced expression of hepatic acyl-CoA synthase and microsomal triglyceride transfer protein mRNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation. Hepatology 27:557-562, 1998

• 11) Svedberg J, Bjorntorp P, Smith U et al:Free-fatty acid inhibition of insulin binding, degradation, and action in isolated rat hepatocytes. Diabetes 39:570, 1990
  pubmed

• 12) Stromblad G, Bjorntorp P:Reduced hepatic insulin clearance in rats with dietary induced obesity. Metabolism 35:323, 1986
  pubmed

• 13) Jiao S, Matsuzawa Y, Matsubara K et al:Abnormalities of plasma lipoproteins in a new genetically obese rat with non-insulin-dependent diabetes mellitus (Wistar fatty rat). Int J Obes 15:487, 1991

• 14) Jiao S, Matsuzawa Y, Matsubara K et al:Increased activity of intestinal acyl-CoA:cholesterol acyltransferase in rats with streptozotocin-induced diabetes and restoration by insulin supplementation. Diabetes 37:342-346, 1988
  pubmed

• 15) Despres JP, Ferland M, Moorjani S et al:Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese women. Arteriosclerosis 9:485-492, 1989
  pubmed

• 16) Arai T, Hirano K, Yamashha S et al:Marked increase of plasma cholesteryl ester transfer protein in obese subjects-correlation between plasma CETP activity, high density lipoprotein-cholesterol levels and body fat distribution. Arterioscl Thromb 14:1129-1136, 1994

• 17) Hegele RA:Premature atherosclerosis associated with monogenic insulin resistance. Circulation 103:2225-2229, 2001
  pubmed

• 18) Cao H, Hegele RA:Nuclear lamin A/C R482Q mutation in Canadian kindred with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 9:109-112, 2000

• 19) Miyaoka K, Kuwasako T, Hirano K et al:CD36 deficiency associated with insulin resistance. Lancet 357:651-652, 2001

• 20) Altman TJ, Glazier AM, Wallace CA et al:Identification of Cd36(Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 21:76-83, 1999

5 ◎ トリグリセライド、HDLコレステロールと動脈硬化

P.71 掲載の参考文献

• 1) Gofman J, Strisower B, de Lalla O et al:Index of coronary artery atherogenesis. Mod Med:21:119-140, 1953

• 2) Albrink MJ, Mann EB:Serum triglycerides in coronary artery disease. Arch Intern Med 103:4-8, 1959

• 3) Austin MA:Plasma triglyceride and coronary heart disease. Arterioscl Thromb 11:2-14 1991
  pubmed

• 4) Page IH, Berrettoni JN, Butkus A, Sones FM:Prediction of coronary heart disease based on clinical suspicion, age, total cholesterol, and triglyceride. Circulation 62:625-645, 1970

• 5) Hulley SB, Roseman RH, Bawol RD, Brand RJ:Epidemiology as a guide to clinical decisions:the association between triglyceride and coronary heart disease. N Engl J Med 302:1383-1389, 1980

• 6) Criqui MH, Heiss G, Cohn R et al:Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 328:1220-1225, 1993
  pubmed

• 7) Carlson LA, Bottinger LE:Risk factor for ischemic heart disease in men and women. Results of the 19-year follow-up of the Stockholm Prospective Study. Acta Med Scand 218:207-211, 1985

• 8) Kukita H, Hiwada K:Epidemiology of hypertriglyceridemia in relation to atherosclerotic cardiovascular diseases. Current Advances in Triglycerides and Atherosclerosis (Yamamoto A, Nakamura H, Nakai T ed), Churchill Livingstone Japan, Tokyo, 1994, pp11-26

• 9) Yamamoto A, Yamamura T, Kawaguchi A et al:Triglyceride and glucose intolerance as a risk factor for coronary heart disease. Cardiology 78:185-193, 1991
  pubmed

• 10) Castelli WP:Lipids, risk factors and ischemic heart disease. Atherosclerosis 124(Supp1):S1-S9, 1996

• 11) 山本 章(日本人における高脂血症調査研究班):日本人の血清脂質(HDL). 動脈硬化 12:1345-1349, 1985

• 12) Castelli WP:Cholesterol and lipids in the risk of coronary artery disease. The Framingham Heart Study. Canad J Cardiol 4 (Suppl A):5a-10a, 1988

• 13) Assmann G, Schulte H, von Eckardstein A:Hypemiglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77:1179-1184, 1996
  pubmed

• 14) National Heart, Lung, and Blood Institute Conference Development Panel. Treatment of hypertriglyceridemia. J Am Med Assoc 251:1196-1200, 1984

• 15) Miller M:The epidemiology of the triglyceride as a coronary artery disease risk factor. Clin Cardiol 22(Suppl II):1-6, 1999

• 16) 茎田仁志, 日和田邦男:冠動脈硬化症の疫学における高トリグリセライド血症の意義. Therap Res 14:551-558, 1991

• 17) The international Committee for the Education of Hypertriglyceridemia as a Vascular Risk Factor:the Hypertriglyceridemia risk and management. Am J Cardiol 68 (Suppl A):1-42, 1991

• 18) Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel II):Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high cholesterol in adults. JAMA 269:3015-3023, 1993

• 19) NIH Consensus Development Panel on Triglyceride, High Density Lipoprotein, and Coronary Heart-Disease:Triglyceride, high-density lipoprotein and coronary heart disease. JAMA 269:505-510, 1993
  pubmed

• 20) Miller NE, Forde oH, Thelle DS et al:The Tromso heart-study:igh-density lipoprotein and coronary heart-disease:a prospective case-control study. Lancet 1:965-968, 1977

• 21) 山本 章, 石川勝憲, 松澤佑次ほか:動脈硬化症における血清リポ蛋白異常について. 動脈硬化 3:261-265, 1975

• 22) Castelli WP, Doyle JT, Gordon T et al:HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 55:767-772, 1977
  pubmed

• 23) Goldbourt u, Yaari S, Medalie JH:Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year fbllow-up of 8000 men. Arterioscl Thromb Vascul Biol 17:107-113, 1997

• 24) Tanne D, Yaari S, Goldbourt U:High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the lsraeli lschemic Heart Disease Study. Stroke 28:83-87, 1997

• 25) Assmann G, Shulte H:Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease(the PRoCAM experience) . Prospective Cardiovascular Mdnster study. Am J Cardiol 70:733-737, 1992

• 26) Mannien V, Tenkanen L, Koskinen P et al:Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85:37-45, 1992

• 27) Jeppesen J, Hein HO, Suadicani P, Gyntelberg F:Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscl Thromb Vascul Biol 17:1114-1120, 1997

• 28) Jeppesen J, Hein oH, Suadicani P et al:Low triglycerides-high high-density lipoprotein cholesterol and rich of ischemic heart disease. Arch Intern Med 161:361-366, 2001

• 29) Hokanson JE, Austin MA:Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level:a meta-analysis of population-based prospective study. J Cardiovascular Risk 3:213-219, 1996

• 30) Depres J-P, Lemieux I, Dagenais G-R et al:HDL-cholesterol as a marker of coronary heart disease risk:the Quebec cardiovascular study. Atherosclerosis 153:263-272, 2000

• 31) Gaziano JM, Hennekens CH, O'Donnell CJ et al:Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 96:2520-2525, 1997

• 32) Miller M, Seidler A, Moalemi A, Pearson TA:Normal triglyceride levels and coronary artery disease events:the Baltimore Coronary observational Long-term Study. JACC 31:1252-1257, 1998
  pubmed

• 33) Executive Summary of The Third Report of The National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001

• 34) Stampfer MJ, Krauss RM, Ma J et al:A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276:882-886, 1996

• 35) Patsch JR, Miesenbock G, Hopferwieser T et al:Relation of triglyceride metabolism and coronary artery disease:studies in the postprandial state. Arteriocl Thromb 12:1336-1345, 1992
  pubmed

• 36) 多田紀夫:食後高脂血症と高レムナント血症-脂肪負荷試験の意義. 動脈硬化 27:319-325, 2000

• 37) Sharrett AR, Chambless C, Heiss G et al:Association of postprandial triglyceride and retinyl palmitate responses with a symptomatic carotid artery atherosclerosis in middle-aged men and women. Arterioscl Thromb Vascul Biol 15:2122-2129, 1995

• 38) Sacks F, Tonkin A, Shepherd J et al:Prospective pravastatin pooling project:Relative risk reduction by baseline HDL and TG concentrations (abstract of XII th Int Symp Atherosclerosis:MoP27:W6). Atherosclerosis 151:41, 2000

6 ◎ HDLの疫学について

P.81 掲載の参考文献

• 1) 三井田孝:コレステロール逆転送系の分子機構. 日本臨床 59 (増2):463-467, 2001

• 2) Miller NE, Thelle DS, Forde OH et al:The Tromso heart-study. High-density lipoprotein and coronary heart-disease:a prospective case-control study. Lancet i:965-968, 1977
  pubmed

• 3) Gordon DJ, Probstfield JL Garrison RJ et al:High-density lipoprotein cholesterol and cardiovascular disease:four prospective American Studies. Cirulation 79:8-15, 1989

• 4) Gordon DJ:Epidemiology of lipoproteins. Lipoproteins in health and disease. (Betteridge DJ, Illingworth DR, Shepherd J eds) , 1st ed, Arnold, London, 1999, pp587-595

• 5) Foody JM, Ferdinand FD, Pearce GL et al:HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery:20-year experience from the Cleveland Clinic Foundation. Circulation 102 (suppl III):90-94, 2000

• 6) Kitamura A, Iso H, Naito Y et al:High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 89:2533-2539, 1994
  pubmed

• 7) 垂井清一郎:日本人における高脂血症とその合併症. 動脈硬化 18:1-16, 1990

• 8) Tanne D, Yaari S, Goldbourt u:High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the lsraeli lschemic Heart Disease Study. Stroke 28:83-87, 1997

• 9) Lindenstrom E, Boysen G, Nyboe J:Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease:the Copenhagen city heart study. BMJ 309:1145, 1994

• 10) 藤島正敏:日本人の脳血管障害. 日内会誌 85:1407-1418, 1996

• 11) Jeppesen J, Hein HO, Suadicani P et al:Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen male study. Circulation 97:1029-1036, 1998
  pubmed

• 12) Assmann G, Cullen P Schulte H:The Munster Heart Study(PROCAM):Results of follow-up at 8 years. Eur Heart J 19 (Suppl A):A2-11, 1998

• 13) Agerholm-Larsen B, Nordestgaard BG, Steffensen R et al:Elevated HDL cholesterol is a riskfactor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 101:1907-1912, 2000

• 14) Hirano K, Yamashita S, Nakajima N et al:Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the omagari area of Japan:Marked hyperalphalipo-proteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17:1053-1059, 1997

• 15) Zhong S, Sharp DS, Grove JS et al:Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97:2917-2923, 1996

• 16) Moriyama Y, Okumura T, Inazu A et al:A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 27:659-667, 1998

• 17) Rubins HB, Robins SJ, Collins D et al:Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl J Med 341:410-418, 1999
  pubmed

• 18) Miida T, Yamaguchi T, Tsuda T et al:High pre β 1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet. Atherosclerosis 138:129-134, 1998

• 19) Miida T, Sakai K, ozaki K et al:Bezafibrate increases pre β 1-HDL at the expense of HDL2b in hypertriglyceridemia. Arterioscler Thromb Vasc Biol 20:2428-2433, 2000

7 ◎ combined hyperlipidemia

P.95 掲載の参考文献

• 1) Goldstein JL, Schrott HG, Hazzard WR et al:Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin invest 52:1544-1568, 1973
  pubmed

• 2) Nikkila EA, Aro A:Family study of serum lipids and lipoproteins in coronary heart-disease. Lancet 1:954-959, 1973

• 3) Rose HG, Kranz P, Weinstock M et al:Inheritance of combined hyperlipoproteinemia:evidence for a new lipoprotein phenotype. Am J Med 54:148-160, 1973
  pubmed

• 4) Brunzell JD, Schrott HG, Motulsky AG et al:Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 25:313-320, 1976
  pubmed

• 5) Kane JP, Havel RJ:Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. The metabolic and molecular basis of inherited disease (Scriber CR et al ed) , 7th ed, McGraw-Hill Inc. , NY, 1995, pp 1981-2030

• 6) Shamir R, Tershakovec AM, Gallagher PR et al:The influence of age and relative weight on the presentation of familial combined hyperlipidemia in childhood. Atherosclerosis 121:85-91, 1996
  pubmed

• 7) Wojciechowski AP, Farrall M, Cullen P et al:Familial combined hyperlipidaemia linked to the apolipoprotein AI-CII-AIV gene cluster on chromosome 11q23-q24. Nature 349:161-164, 1991

• 8) Yang WS, Nevin DN, Iwasaki L et al:Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. J Lipid Res 37:2627-2637, 1996
  pubmed

• 9) Pihlajamaki J, Rissanen J, Valve R et al:Different regulation of free fatty acid levels and glucose oxidation by the Trp64Arg polymorphism of the beta3-adrenergic receptor gene and the promoter variant(A-3826G) of the uncoupling protein l gene in familial combined hyperlipidemia. Metabolism 47:1397-1402, 1998
  pubmed

• 10) Pihlajamaki J, Miettinen R, Valve R et al:The Pro 12A1a substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia. Atherosclerosis 151:567-574, 2000

• 11) Pihlajamaki J, Rissanen J, Heikkinen S et al:Codon 54 polymorphism of the human intestinal fatty acid binding protein 2 gene is associated with dyslipidemias but not with insulin resistance in patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 17:1039-1044, 1997

• 12) Allayee H, Dominguez KM, Aouizerat BE et al:Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia. J Lipid Res 41:245-252, 2000

• 13) Aouizerat BE, Allayee H, Bodnar J et al:Novel genes for familial combined hyperlipidemia. Curr Opin Lipidol 10:113-122, 1999
  pubmed

• 14) Pajukanta P, Terwilliger JD, Perola M et al:Genomrwide scan for familial combined hyperlipidemia genes in Finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol and apolipoprotein B levels. Am J Hum 6enet 64:1453-1463, 1999

• 15) Aouizerat BE, Allayee H, Rotter JI et al:Identification of TNFRSFIB as a novel modifier gene in familial combined hyperlipidemia. Hum Mol Genet 9:2067-2074, 2000

• 16) Austin MA, McKnight B, Edwards KL et al:Cardiovascular disease mortality in familial forms of hypertriglyceridemia:A20-year prospective study. Circulation 101:2777-2782, 2000

• 17) Bredie SJ, Vogelaar JM, Demacker PN et al:Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia. Atherosclerosis 126:313-324, 1996

• 18) Geurts JM, Janssen RG, van Greevenbroek MM et al:Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia. Am J Hum Genet 58:812-822, 1996

• 19) Pihlajamaki J, Karjalainen L, Karhapaa P et al:G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 20:1789-1795, 2000
  pubmed

• 20) Williams RR, Hopkins PN, Hunt SC et al:Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah. Arch intern Med 150:582-588, 1990
  pubmed

• 21) 齋藤 康:安房地区における家族性複合型高脂血症の疫学調査. 厚生省特定疾患調査 研究原発性高脂血症調査研究班平成9年度研究報告(班長 北 徹), 1998, pp7-12

• 22) 齋藤 康:安房地区における家族性複合型高脂血症の疫学調査. 厚生省特定疾患調査 研究原発性高脂血症調査研究班平成10年度研究報告(班長 北 徹), 1999, pp5-9

• 23) 垂井清一郎:高脂血症の分類と診断基準. 厚生省特定疾患調査研究原発性高脂血症 調査研究班昭和62年度研究報告書(班長 垂井清一郎), 1987, pp26-34

• 24) 馬渕 宏:家族調査により確定診断した家族性複合型高脂血症の血清脂質と冠動脈硬化症. 厚生省特定疾患調査研究原発性高脂血症調査研究班平成10年度研究報告(班長 北 徹), 1999, pp24-28

8 ◎ combined hyperlipidemiaの成因

P.108 掲載の参考文献

• 1) Goldstein JL, Schrott HG, Hazzard WR et al:Hyperlipidemia in coronary heart disease:II. genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52:1544-1568, 1973
  pubmed

• 2) Grundy SM, Chait A, Brunzell JD:Familial combined hyperlipidemia workshop. Arteriosclerosis 7:203-207, 1987

• 3) de Graaf J, Stalenhoef AFH:Defects of lipoprotein metabolism in familial combined hyperlipidemia. Curr Opin Lipidol 9:189-196, 1998

• 4) Aouizerat BE, Allayee H, Bodnar J et al:Novel genes for familial combined hyperlipidemia. Curr Opin Lipidol 10:113-122, 1999
  pubmed

• 5) Rauh G, Schuster H, Muller B et al:Genetic evidence from 7 families that the apolipoprotein B gene is not involved in familial combined hyperlipidemia. Atherosclerosis 83:81-87, 1990

• 6) Coresh J, Beaty TH, Kwiterovich PO et al:Pedigree and sib-pair linkage analysis suggest the apolipoprotein B gene is not major gene influencing plasma apolipoprotein B levels. Am J Hum Genet 50:1038-1045, 1992

• 7) Babirak SP, Iverius P-H, Fujimoto WY et al:Detection and characterization of the hetero-zygote state for lipoprotein lipase deficiency. Arteriosclerosis 9:326-334, 1989

• 8) Babirak SP, Brown BG, Brunzell JD:Familial combined hyperlipidemia and abnomial lipoprotein lipase. Arterioscler Thromb 12:1176-1183, 1992
  pubmed

• 9) Nevin DN, Brunzell JD, Deeb SS:The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity. Arterioscler Thromb 14:869-873, 1994
  pubmed

• 10) Williams KJ, Petrie KA, Brocia RW et al:Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitor:a possible pathophysiologic explanation for familial combined hyperlipidemia. J Clin invest 88:1300-1306, 1991

• 11) Pajukanta P, Porkka KVK, Antikainen M et al:No evidence of linkage between familial combined hyperlipidemia and gene encoding lipolytic enzymes in Finnish families. Arterioscler Thromb Vasc Biol 17:841-850, 1997

• 12) Hoffer MJV, Snieder H, Bredie SJH et al:The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia. Atherosclerosis 151:443-450, 2000

• 13) Pihlajamaki J, Karjalainen L, Karhapaa P et al:G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial hyperlipidemia. Arterioscler Thromb Vasc Biol 20:1789-1795, 2000
  pubmed

• 14) Hayden MR, Kirk H, Clark C et al:DNA polymorphisms in and around the apo-A1-C III genes and genetic hyperlipidemia. Am J Hum Genet 40:421-430, 1987
  pubmed

• 15) Wojciechowski AP, Farrall M, Cullen P et al:Familial combined hyperlipidaemia linked to the apolipoprotein A I-CIII-A IV gene cluster on chromosome 11q23-q24. Nature 349:161-164, 1991

• 16) Wijsman EM, Brunzell JD, Jarvik GP et al:Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein A I-CIII-A IV gene complex. Arterioscler Thromb Vasc Biol 18:215-226, 1998

• 17) Dallinga-Thie GM, Bu X-D, Van Linde-Sibenius Trip M et al:Apolipoprotein A-I/C-III/ A-IV gene cluster in familial combined hyperlipidemia:effects on LDL-cholesterol and apolipoprotein B and C-III . J Lipid Res 37:136-147, 1996

• 18) Pajukanta P, Nuotio I, Terwilliger JD et al:Linkage of familial combied hyperlipidaemia to chromosome 1q21-q23. Nature Genet 18:369-373, 1998

• 19) La Ville A, Turner PR, Pittilo RM et al:Hereditary hyperlipidemia in the rabbit due to overproduction of lipoproteins:1. biochemical studies. Arteriosclerosis 7:105-112, 1987

• 20) Beaty TH, Kwiterovich PO, Laville A et al:Genetic analysis of total cholesterol and triglycerides in a pedigree of St. Thomas rabbits. J Lipid Res 30:387-394, 1989

• 21) Shachter NS, Ebara T, Ramakrishnan R et al:Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein CI. J Clin Invest 98:846-855, 1996

• 22) Masucci-Magoulas L, Goldberg IJ, Bisgaier CL et al:A mouse model with teatures of familial combined hyperlipidemia. Science 275:391-394, 1997
  pubmed

• 23) Castellani LW, Weinreb A, Bodnar J et al:Mapping a gene for combined hyperlipidemia in a mutant mouse strain. Nature Genet 18:374-377, 1998

P.115 掲載の参考文献

• 1) Goldstein JL, Schrott HG, Hazzard WR et al:Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52:1544-1568, 1973
  pubmed

• 2) Rose HG, Kranz P, Weinstock M et al:Inheritance of combined hyperlipoproteinemia:evidence for a new lipoprotein phenotype. Am J Med 54:148-160, 1973
  pubmed

• 3) Nikkila EA, Aro A:Family study of serum lipids and lipoproteins in coronary heart-disease. Lancet 1:954-959, 1973

• 4) Brunzell JD, Schrott HG, Motulsky AG et al:Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 25:313-320, 1976
  pubmed

• 5) Kwiterovich JR:Genetics and molecular biology of familial combined hyperlipidemia. Curr Opin Lipidol 4:133-143, 1993

• 6) Matsuzawa Y, Shimomura I, Nakamura T et al:Pathophysiology and pathogenesis of visceral fat obesity. Ann NY Acad Sci 676:270-278, 1993
  pubmed

• 7) Babirak SP, Iverius PH, Fujimoto WY et al:Detection and characterization of the hetero-zygote state for lipoprotein lipase deficiency. Arteriosclerosis 9:326-334, 1989

• 8) Aitman TJ, Godsland IF, Farren B et al:Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 17:748-754, 1997
  pubmed

• 9) Kaljalainen L, Pihlajamaki J, Karhapaa P et al:Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia:a precursor defect for dyslipidemia? Arterioscler Thromb Vasc Biol 18:1548-1553, 1998
  pubmed

• 10) Kissebah AH, Alfarsi S, Evans DJ:Low density lipoprotein metabolism in familial combined hyperlipidemia. Mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis 4:614-624, 1984
  pubmed

• 11) Venkatesan S, Cullen P, Pacy P et al:Stable isotopes show a direct relationbetween VLDL apoB overproductinand serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb l 3:1110-1118, 1993

• 12) Coresh J, Beaty TH, Kwiterovich Jr PO et al:Pedigree and sib-pair linkage analysis suggest the apolipoprotein B gene is not the major gene influencing plasma apolipoprotein B levels. Am J Hum Genet 50:1038-1045, 1992

• 13) Aguilar-Salinas CA, Hugh P, Barrett R et al:A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy. Arterioscler Thromb Vasc Biol 17:72-82, 1997

• 14) Ascaso JF, Lorente R, Merchante A et al:Insulin resistance in patients with familial combined hyperlipidemia and coronary artery disease. Am J Cardiol 80:1484-1487, 1997
  pubmed

• 15) Bredie SJ, Tack CJ, Smits P et al:Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives. Arterioscler Thromb Vasc Biol 17:1465-1471, 1997
  pubmed

• 16) Purnell JQ, Kahn SE, Schwartz RS et al:Relationship of insulin sensitivity and ApoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 21:567-572, 2001
  pubmed

• 17) Eckel RH:Familial combined hyperlipidemia and insulin resistance:distant relatives linked by intra-abdominal fat？Arterioscler Thromb Vasc Biol 21:469-470, 2001
  pubmed

• 18) Shimomura I, Hammer RE, Richardson JA et al:Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue:model for congenital generalized lipodystrophy. Genes Dev 12:3182-3194, 1998
  pubmed

• 19) Williams RR, Hunt SC, Hopkins PN et al:Familial dyslipidemic hypertension. Evidence from 58 utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA 259:3579-3586, 1988
  pubmed

• 20) Keulen ET, Voors-Pette C, de Bruin TW:Familial dyslipidemic hypertension syndrome:familial combined hyperlipidemia, and the role of abdominal fat mass. Am J Hypertens 14:357-363, 2001

• 21) Kuriyama H, Yamashita S, Shimomura I et al:Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation. Hepatology 27:557-562, 1998
  pubmed

• 22) Nakamura T, Tokunaga K, Shimomura I et al:Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107:239-246, 1994

• 23) Kobayashi J, Tashiro J, Murano S et al:Lipoprotein lipase mass and activity in post-heparin plasma from subjects with intra-abdominal visceral fat accumulation. Clin Endocrinol (Oxf) 48:515-520, 1998
  pubmed

• 24) Castellani LW, Weinreb A, Bodnar J et al:Mapping a gene for combined hyperlipidaemia in a mutant mouse strain. Nat Genet 18:374-377, 1998

• 25) Pajukanta P, Nuotio I, Terwilliger JD et al:Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet 18:369-373, 1998
  pubmed

• 26) Peters JM, Bames R, Bennett L et al:Localization of the gene for familial partial lipodystroph y(Dunnigan variety) to chromosome 1q21-22. Nat Genet 18:292-295, 1998

• 27) Bredie SJ, de Bruin TW, Demacker PN et al:Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 75:348-353, 1995
  pubmed

• 28) 藤岡滋典ほか:肥満におけるインスリン感受性の検討. 第10回日本肥満学会記録 68, 1990

• 29) Fujioka S, Matsuzawa Y, Tokunaga K et al:Improvement of glucose and lipid metabolism associated with selective reduction of intra-abdominal visceral fat in premenopausal women with visceral fat obesity. Int J Obes Relat Metab Disord 15:853-859, 1991

• 30) Shimomura I, Tokunaga K, Kotani K et al:Marked reduction of acyl-CoA synthetase activity and mRNA in intra-abdominal visceral fat by physical exercise. Am J Physiol 265:E44-E50, 1993
  pubmed

• 31) Keno Y, Matsuzawa Y, Tokunaga K et al:High sucrose diet increases visceral fat accumulation in VMH-lesioned obese rats. Int J Obes Relat Metab Disord 15:205-211, 1991

9 ◎ TG-richリポ蛋白の代謝

P.129 掲載の参考文献

• 1) Marinetti GV:Disorders of lipid metabolism, Plenum Press, New York, 1990, pp1-226

• 2) Havel RJ, Goldstein JL, Brown MS:Lipoproteins and lipid transport. Metabolic Control and Disease (Bondy PK, Rosenberg LE ed) , WB Saunders, Philadelphia, 1980, pp393-494

• 3) Kane JP, Havel RJ:Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. The Metabolic and molecular Bases of inherited disease (Scriver CR, Beaudet AL, Sly WS et al ed) , McGraw-Hill, Inc. , New York, 1995, pp1853-1885

• 4) Mayes PA:Metabolism of Lipid. Harper's review of biochemistry (Martin DW, Mayes PA, Rodwell VW ed) , 19th ed, Lange Medical Publications, Maruzen Asia, 1983, pp201-247

• 5) Havel RJ, Kane JP:Introduction:structure and metabolism of plasma lipoproteins. The Metabolic and molecular Bases of inherited disease(Scriver CR, Beaudet AL, Sly WS et, aled) , McGraw-Hill, Inc. , New York, 1995, pp1841-1851

• 6) 池田康行, 山本 章:酵素の働き-代謝マップ上の各種酵素の作用部位と異常. わかりやすい脂質代謝とその異常(五島雄一郎編), メディカルトリビューン, 東京, 1991, pp24-27

• 7) Ikeda Y, Takagi A, Yamamoto A:Purification and characterization of lipoprotein lipase and hepatic triglyceride lipase from human postheparin plasma:production of monospecific antibody to the individual lipase. Biochim Biophys Acta 1003:254-269, 1989

• 8) Wion KL, Kirchgessner TG, Lusis AJ et al:Human lipoprotein lipase complementary DNA sequence. Science 235:1638-1641, 1987
  pubmed

• 9) Kirchgessner TG, Chuat JC, Heinzmann C et al:Organization of the human lipoprotein lipasegene and evolution of the lipase gene family. Proc Natl Acad Sci USA 86:9647-9651, 1989
  pubmed

• 10) Martin GA, Busch SJ, Meredith GD et al:Isolation and cDNA sequence of human postheparin plasma hepatic triglyceride lipase. J Biol Chem 263:10907-10914, 1988
  pubmed

• 11) Cai SJ, Wong DM, Chen SH et al:Stmcture of the human hepatic triglyceride lipase gene. Biochemistry 28:8966-8971, 1989
  pubmed

• 12) Hesler CB, Swenson TL, Tall AR:Purification and characterization of a human plasma cholesteryl ester transfer protein. J Biol Chem 262:2275-2282, 1987
  pubmed

• 13) Drayna D, Jarnagin AS, McLean J et al:Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 327:632-634, 1987
  pubmed

• 14) Agellon LB, Quinet EM, Gillette TG et al:organization of the human cholesteryl ester transfer protein gene. Biochemistry 29:1372-1376, 1990
  pubmed

• 15) McLean J, Fielding C, Drayna D et al:Cloning and expression of human lecithin-cholesterol acyltransferase cDNA. Proc Natl Acad Sci uSA 83:2335-2339, 1986
  pubmed

• 16) McLean J, Wion K, Drayna D et al:Human lecithin-cholesterol acyltransferase gene:complete gene sequence and sites of expression. Nucleic Acids Res 14:9397-9406, 1986
  pubmed

• 17) Glomset JA, Assmann G, Gjone E et al:Lecithin:cholesterol acyltransferase deficiency and fish eye disease. The Metabolic and molecular Bases of inherited disease(Scriver CR, Beaudet AL, Sly WS et al ed) , McGraw-Hill, Inc. , New York, 1995, pp1933-1951

• 18) Langin D, Laurell H, Holst LS et al:Gene organization and primary structure of human hormone-sensitive lipase:possible significance of a sequence homology with a lipase of Moraxella TA144, an antarctic bacterium. Proc Natl Acad Sci USA 90:4897-4901, 1993
  pubmed

• 19) Wetterau JR, Lin MC, Jamil H:Microsomal triglyceride transfer protein. Biochim Biophys Acta 1345:136-150, 1997
  pubmed

• 20) Langin D, Holm C, Lafontan M:Adipocyte homlone-sensitive lipase:a major regulator of lipid metabolism. Proc Nutr Soc 55:93-109, 1996

• 21) Brunzell JD:Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. The Metabolic and molecular Bases of inherited disease (Scriver CR, Beaudet AL, Sly WS et al ed) , 6th ed, McGraw-Hill, Inc. , New York, 1995, pp1128-1180

• 22) Takagi A, Ikeda Y, Mori A et al:A newly identified heterozygous lipoprotein lipase gene mutation (Cys239→stop/TGC972→TGA;LPLobama) in a patient with primary type IV hyperlipoproteinemia. J Lipid Res 35:2008-2018, 1994

• 23) Ikeda Y, Takagi A, Yamamoto A et al:Elucidation of an underlying etiology of primary type IV hyperlipoproteinemia:heterozygous lipoprotein lipase deficiency as a causal genetic disorder. Current Advances in Triglyceride and Atherosclerosis (Yamamoto A, Nakamura H, Nakai T ed) , Churchill Livingstone Japan, Tokyo, 1994, pp173-186

• 24) 堤 善多ほか:低リポ蛋白リパーゼ群でのアルコールによる内因性高トリグリセライド血症の発症-禁酒による正脂血化-. 日本消化器病学会誌 92:951, 1995

• 25) Takagi A, Ikeda Y, Takeda E et al:A newly identified lipoprotein lipase (LPL) gene mutation (F270L) in a Japanese patient with familial LPL deficiency. Biochim Biophys Acta 1502:433-446, 2000

• 26) Eisenberg S, Gavish D, Oschry Y et al:Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia-Reversal toward normal with bezafibrate treatment. J Clin Invest 74:470-482, 1984
  pubmed

• 27) Austin MA, Breslow JL, Hemekens CH et al:Low-density lipoprotein subclass pattems and risk of myocardial infarction. J Am Med Assoc 260:1917-1921, 1988

• 28) Deckelbaum RJ, Olivecrona T, Eisenberg S:Plasma lipoproteins in hyperlipidemia:roles of neutral lipid exchange and lipase. Treatment of Hyperlipoproteinemia (Carlson LA, Olsson AG ed) , Raven Press, New York, 1984, pp85-93

• 29) Ikeda Y, Ashida Y, Takagi A et al:Mechanism of the production of small dense LDL (sLDL) in hypertriglyceridemia. ATHEROSCLEROSIS IX (Jacotot B, Mathe D, Fruchart JC ed) , Elsevier, Amsterdam, 1998, pp777-788

• 30) Millar JS, Packard CJ:Heterogeneity of apolipoprotein B-100-containing lipoproteins:what we have learnt from kinetic studies. Curr Opin Lipidol 9:197-202, 1998
  pubmed

10 ◎ トリグリセライド代謝、HDL代謝と調節遺伝子

P.136 掲載の参考文献

• 1)Kanai M, Raz A, Goodman DS:Retinol-binding protein:the transport protein for vitamin A in human plasma. J Clin Invest 47:2025, 1968
  pubmed

• 2) Glover J:Retinol-binding proteins. Vitam Horm 31:1-42, 1973
  pubmed

• 3) Goodman DS:Vitamin A transport and retinol-binding protein metabolism. Vitam Horm 32:167-180, 1974
  pubmed

• 4) Saari JC, Bredberg L, Garwin GG:Identification of the endogenous retinoids associated with three cellular retinoid-binding proteins from bovine retina and retinal pigment epithelium. J Biol Chem 257:13329-13333, 1982
  pubmed

• 5) Giguere V, ong ES, Segui P et al:Identification of a receptor for the morphogen retinoic acid. Nature 330:624-629, 1987
  pubmed

• 6) Petkovich M, Brand NJ, Krust A et al:A human retinoic acid receptor which belongs to thefamily of nuclear receptors. Nature 330:444-450, 1987

• 7) Mangelsdorf DJ, ong ES, Dyck JA et al:Nuclear receptor that identifies a novel retinoic acidresponse pathway. Nature 345:224-229, 1990
  pubmed

• 8) Bjorkegren J, Veniant M, Kim SK et al:Lipoprotein secretion and triglyceride stores in the heart. J Biol Chem, in press

• 9) Wetterau JR, Gregg RE, Harrity TW et al:An MTP inhibitor that normalizes atherogeniclipoprotein levels in WHHL rabbits. Science 282:751-754, 1998
  pubmed

• 10) ong DE:Vitamin A-binding proteins. Nutr Rev 43:225-232, 1985
  pubmed

• 11) Harrison EH, Hussain MM:Mechanisms involved in the intestinal digestion and absorption of dietary vitamin A. J Nutr 131:1405-1408, 2001
  pubmed

• 12) Suruga K, Suzuki R, Goda T et al:Unsaturated fatty acids regulate gene expression of cellular retinol-binding Protein, type II in rat jejunum. J Nutr 125:2039-2044, 1995
  pubmed

• 13) Mangelsdorf DJ, Umesono K, Kliewer SA et al:A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell 66:555-561, 1991
  pubmed

• 14) Mochizuki K, Suruga K, Kitagawa M et al:Modulation of the expression of peroxisome proliferator-activated receptor-dependent genes through disproportional expression of two subtypes in the small intestine. Arch Biochem Biophys 389:41-48, 2001
  pubmed

• 15) Sharp D, Ricci B, Kienzle B et al:Human microsomal triglyceride transfer protein large subunit gene structure. Biochemistry 33:9057-9061, 1994
  pubmed

• 16) Gregg RE, Wetterau JR:The molecular basis of abetalipoproteinemia. Curr Opin Lipidol 5:81-86, 1994
  pubmed

• 17) Wetterau JR, Aggerbeck LP, Bouma ME et al:Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 258:999-1001, 1992
  pubmed

• 18) Shalp D, Blinderman L, Combs KA et al:Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 365:65-69, 1993

• 19) Lin MC, Arbeeny C, Bergquist K et al:Cloning and regulation of hamster microsomal triglyceride transfer protein. The regulation is independent from that of other hepatic and intestinal proteins which participate in the transport of fatty acids and triglycerides. J Biol Chem 269:29138-29145, 1994
  pubmed

• 20) Kuriyama H, Yamashita S, Shimomura I et al:Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypemhglyceridemic rat with visceral fat accumulation. Hepatology 27:557-562, 1998
  pubmed

• 21) Karpe F, Lundahl B, Ehrenborg E et al:A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol 18:756-761, 1998
  pubmed

• 22) Bjorn L, Leren TP, Ose L et al:A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein(MTP-493G/T) influences lipoprotein phenotype in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 20:1784-1788, 2000

• 23) Bernard S, Touzet S, Personne I et al:Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 43:995-999, 2000
  pubmed

• 24) Couture P, Otvos JD, Cupples LA et al:Absence of association between genetic variation in the promoter of the microsomal triglyceride transfer protein gene and plasma lipoproteins in the Framingham offspring Study. Atherosclerosis 148:337-343, 2000
  pubmed

• 25) Hagan DL, Kienzle B, Jamil H et al:Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators. J Biol Chem 269:28737-28744, 1994
  pubmed

• 26) Lin MC, Li JJ, Wang EJ et al:Ethanol down-regulates the transcription of microsomal triglyceride transfer protein gene. FASEB J 11:1145-1152, 1997
  pubmed

P.154 掲載の参考文献

• 1) 井上郁夫, 片山茂裕:抗高脂血症治療薬の開発の現状と臨床試験のあり方. 臨床薬理 30:729, 1999

• 2) 井上郁夫, 山田信博:介入試験の意味すること. 内科 79:181-182, 1997

• 3) 井上郁夫, 高橋慶一, 片山茂裕:耐糖能異常にみられるリポ蛋白異常. 日本臨床 54:2672-2678, 1996

• 4) 梅園和彦:核内受容体の構造分類と内分泌情報の統合. 日本臨床 56:1693-1698, 1998
  Medical*Online

• 5) 井上郁夫, 高橋慶一, 片山茂裕:フルクトース負荷ラットの肝の脂肪酸結合能へのベザフィブレートの影響. 糖尿病 37(Suppl 1):271, 1994

• 6) Sapone A, Peters JM, Sakai S et al:The human peroxisome proliferator-activated receptorα gene:identification and functional characterization of two natural allelic variants. J Pharmacogenetics 10:321-333, 2000

• 7) Flavell DM, Pineda TI, Jamshidi Y et al:Variation in the PPAR α gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 43:673-680, 2000

• 8) 野原 淳, 水野美保子, 井沢 郎ほか:原発性高脂血症患者におけるperoxisome proliferator-activated receptor α (PPAR α)ミスセンス変異体の同定. 動脈硬化 28 (suppl):134, 2000

• 9) 井上郁夫, 片山茂裕:PPAR αと脂質代謝. Progress in Medicine 19:2451-2459, 1999

• 10) Inoue I, Shino K, Noji S et al:Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commum 246:370-374, 1998

• 11) Staels B, Koenig W, Habib A et al:Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPAR γ activators. Nature 393:790-793, 1998

• 12) Chinetti G, Griglio S, Antonucci M et al:Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273:25573-25580, 1998

• 13) Kim HT, Kim YH, Nam JW et al:Study of 5'-flanking region of human Cu/Zn superoxide dismutase. Biochem Biophys Res Commun 201:1526-1533, 1994
  pubmed

• 14) Yoo HY, Chang MS, Rho HM:Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid. Gene 234:87-91, 1999
  pubmed

• 15) Crapo JD, oury T, Rabouille C et al:Copper, zinc superoxide dismutase is primarily a cytosolic protein in human cells. Proc Natl Acad Sci USA 89:10405-10409, 1992
  pubmed

• 16) Inoue I, Goto S, Matsunaga T et al:The ligands/activators for peroxisome proliferator-activated receptor α (PPAR α) and PPAR γ increase Cu2+, Zn2+-superoxide dismutase (CuZn-SOD) and decrease p22phox message expressions in primary endothelial cells. Metabolism 50(1):3-11, 2001

• 17) Munzel T, Hink u, Heitzer T et al:Role fbr NADPH/NADH oxidase in the modulation of vascular tone. Ann NY Acad Sci 874:386-400, 1999

• 18) Azumi H, Inoue N, Takeshita S et al:Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 100:1494-1498, 1999
  pubmed

• 19) Inoue I, Goto S, Mizotani K et al:Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect:reduction of mRNA levels for interleukin-1 β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPAR α) in primary endothelial cells. Life Sci 67:863-876, 2000

• 20) Yahagi N, Shimano H, Hasty AH et al:A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J Biol Chem 274:35840-35844, 1999
  pubmed

• 21) Luong A, Hannah VC, Brown MS, Goldstein JL:Molecular characterization of human acetyl-CoA synthetase, an enzyme regulated by sterol regulatory element-binding proteins. J Biol Chem 275:26458-26466, 2000
  pubmed

• 22) 井上郁夫, 林 健二, 溝谷香壽美ほか:スタチン系薬の核内受容体PPAR α促進作用 とフィブラート系薬の核内受容体LXR α促進作用. 動脈硬化 28(suppl):114, 2000

• 23) Chinetti G, Lestavel S, Bocher V et al:PPAR α and PPAR γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58, 2001

11 ◎ トリグリセライド、HDLと内皮細胞機能、マクロファージ

P.161 掲載の参考文献

• 1) Manninen V, Tenkanen H, Koskinen P et al:Joint effects of serum triglycerides and LDLcholesterol and HDL cholesterol concentration on coronary heart disease risk in the HelsinkiHeart Study. Implications for treatment. Circulation 85:37-45, 1992

• 2) Kaplan NM:The deadly quartet. upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Archives of Internal Medicine 149:1514-1520, 1989
  pubmed

• 3) Campos E, Nakajima K, Tanaka A et al:Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasm with a monoclonal antibodyto apolipoprotein B-100. J Lipid Res 33:369-380, 1992

• 4) Kugiyama K, Doi H, Takazoe K et al:Remnant lipoprotein levels in fasting serum predictcoronary events in patients with coronary artery disease. Circulation 99:2858-2860, 1999
  pubmed

• 5) Doi H, Kugiyama K, oka H et al:Remnant lipoproteins induce proatherothrombogenicmolecules in endothelial cells through a redox-sensitive mechanism. Circulation 102:670-676, 2000
  pubmed

• 6) Tall AR:Plasma high density lipoproteins」Clin Invest 86:379-384, 1990

• 7) Dansky HM, Charlton SA, Barlow CB et al:Apo A-Iinhibits foam cell formation in ApoE-deficient mice after monocyte adherence to endothelium. J Clin invest 104:31-39, 1999
  pubmed

12 ◎ 高トリグリセライド血症および低HDLコレステロール血症における凝固線溶反応

P.174 掲載の参考文献

• 1) The GUSTO investigator:An interventional randomized trial comparing four thrombolytic strategies for acute, myocardial infarction. N Engl J Med 329:673-682, 1993

• 2) Baj zar J, Mannuel R, Nesheim ME:Purification and characterization of TAFI, a thrombiactivatable fibrinoplysis inhibitor. J Biol Chem 270:14477-14484, 1995

• 3) Parthasarathy S, Barnett J, Fong DS:High density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochem Biophys Acta 1044:275-283, 1990

• 4) Watson DW, Berliner JA, Hama SY et al:Protective effect of high density lipoprotein associated paraoxonase; Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin lhvest 96:2882-2891, 1995

• 5) Navab M, Imes SS, Hama ST et al:Monocyte transmigration induced by modification of low-density lipoprotein in cocultures of human aortic walls is due to induction of monocyte chemotactic protein-1 synthesis and is abolished by high-density lipoprotein. J Clin Invest 88:2039-2046, 1991

• 6) Chung BH, Segrest LP, Smith K et al:Lipolytic surface remmant of triglyceride-rich lipoprotein are cytotoxic to macrophages but not in the presence of high-density lipoprotein. J Clin Invest 83:1363-1374, 1989

• 7) Zeiher AM, Schachinger V, Hohnloser SH et al:Coronary atherosclerotic wall thickning and vascular reactivity in humans:Elevated high-density lipoprotein levels ameriolate abnormal vasoconstriction in early atherosclerosis. Circulation 89:2525-2532, 1994

• 8) Yui Y, Morishita H, Takahashi M et al:Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I(Apo A-I) . A novel function of Apo A-I. J Clin invest 82:803-807, 1988
  pubmed

• 9) Kawaguchi A, Miyao Y, Noguchi T et al:Intravascular tissue factor pathway inhibitor was inversely correlated with HDL cholesterol and post-heparin lipoprotein lipase, but proportional to apolipoprotein A-II. Arterioscler Thromb Vasc Biol 20:251-258, 2000

• 10) Hubbard AR, Jennings CA:Inhibition of the tissue factor-factor VII complex:Involvement of factor Xa and lipoproteins. Thromb Res 46:527-537, 1987
  pubmed

• 11) Lupu C, Lupu F, Demehy u et al:Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 15:2055-2062, 1995
  pubmed

• 12) Ameri A, Kuppuswamly MN, Basu S et al:Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 79:3219-3226, 1992

• 13) Hamsten A, Wiman B, De Faire u et al:Increased plasma level of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313:1157-1163, 1985

• 14) Juhan-Vague I, Pyke SDM, Alessi MC et al:Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 94:2057-2063, 1996
  pubmed

• 15) Juhan-Vague I, Thompson SG, Jespersen J:Involvement of the hemostatic system in the insulin resistance syndrome:a study of 1500 patients with angina pectoris. Arterioscler Thromb13:1865-1873, 1993
  pubmed

• 16) Anfosso F, Chomiki N, Alessi MC et al:Plasminogen activator inhibitor 1 synthesis in the human hepatoma cell line Hep G2:metforrnin inhibits the stimulating effect of insulin. J Clin Invest 91:2185-2193, 1993
  pubmed

• 17) Lundgren CH, Brown NA, Nordt TK et al:Elaboration of type 1 plasminogen activator inhibitor from adipocytes:apotential pathogenetic link between obesity and cardiovascular disease. Circulation 93:106-110, 1996

• 18) Eriksson P, Nilsson L, Karpe Fredrik et al:Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 18:20-26, 1998

• 19) Colluci M, Paramo J, Collen D:Generation in plasma of fast acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 75:818-824, 1985

• 20) Hajjar KA, Hamel N:Identification and characterization of human endothelial cell menbrane binding sites fbr tissue plasminogen activator urokinase. J Biol Chem 265:2908-2916, 1990

• 21) Danesh J, Collins R, Appleby P et al:Fibrinogen, C-reactive protein, albumin or white blood cell count:meta-analyses of prospective studies of coronary heart disease. JAMA 279:1477-1482, 1998
  pubmed

• 22) Halle M, Berg A, Keul J et al:Association between serum fibrinogen concentration and HDL and LDL subfraction phenotypes in healthy men. Arterioscler Thromb Vasc Biol 16:144-148, 1996

• 23) Geng Y, Zhang B, Lotz Ml:Interleukin-6:A regulator of plasma protein gene expression in hepatic and non-hepatic tissues. Mol Biol Med 7:117-130, 1990

• 24) Heinrich J, Balleisen L, Schulte H et al:Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 14:54-59, 1994
  pubmed

• 25) Bums P, Hoffman CJ, Katz JP et al:Vitamin K-dependent clotting factors are elevated in young adults who have close relatives with ischemic heart disease. J Lab Clin Med 122:720-727, 1993

• 26) Skartlien AH, Lyberg-Beckmann S, Holme I et al:Effect of alteration in triglyceride levels on factor VII-phospholipid complexes in plasma. Arteriosclerosis 9:798-801, 1989
  pubmed

• 27) Xu N, Dahl Beck B, Ohlin AK et al:Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. Arterioscler Thromb Vasc Biol 18:33-39, 1998

• 28) Nofer JR, Tepel M, Kehrel B et al:Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets:A novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation 95:1370-1377, 1997

13 ◎ リポ蛋白リパーゼ欠損症、肝性トリグリセライドリパーゼ欠損症

P.192 掲載の参考文献

• 1) Ikeda Y, Takagi A, Yamamoto A:Purification and characterization of lipoprotein lipase and hepatic triglyceride lipase from human postheparin plasma:production of monospecific antibody to the individual lipase. Biochim Biophys Acta 1003:254-269, 1989

• 2) Ikeda Y et al: A sandwich-enzyme immunoassay for the quantification of lipoprotein lipase and hepatic triglyceride lipase in human postheparin plasma using monoclonal antibodies to the corresponding enzymes. J Lipid Res 31:1911-1924, 1990

• 3) 池田康行ほか:リパーゼ測定法. 最新内科学大系9 代謝疾患4 高脂血症・低脂血症 (井村裕夫, 尾形悦郎, 高久史麿, 垂井清一郎編集, 東野一弥, 山本 章専門編集), 中山書店, 東京, 1995, pp347-364

• 4) Brunzell JD:Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. The metabolic and molecular bases of inherited disease (Scriver CR, Beaudet AL, Sly WS et al ed) , McGraw-Hill, New York, 1995, pp 1913-1932

• 5) Nikkila EA:Familial lipoprotein lipase deficiency and related disorders of chylomicron metabolism. The metabolic and molecular bases of inherited disease (Scriver CR, Beaudet AL, Sly WS et al ed) , McGraw-Hill, New York, 1983, pp622-642

• 6) Murthy V, Julien P, Gagne C:Molecular pathobiology of the human lipoprotein lipase gene. Pharmacology & Therapeutics 70:101-135, 1996
  pubmed

• 7) Suga S et al:Identification of homozygous lipoprotein lipase gene mutation in a woman with recurrent aggravation of hypertriglyceridemia induced by pregnancy. J Int Med 243:317-321, 1998

• 8) Benlian P et al:Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 335:848-854, 1996

• 9) Weinstock PH, Bisgaier CL, Aalto-Setala K et al:Severe hypertriglyceridemia, reduced high density lipoprotein, and neonata1 death in lipoprotein lipase knockout mice. J Clin Invest 96:2555-2568, 1995
  pubmed

• 10) Coleman T, Seip RL, Gimble JM et al:CooH-teminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygoutes have elevated triglycerides and impaired enzyme activity. J Biol Chem 270:12518-12525, 1995

• 11) 原田満智子:リポ蛋白リパーゼ欠損症の長期栄養管理:摂取栄養素量と血中トリグリセリド濃度との関係について. 四国医誌 48:126-129, 1992

• 12) Wion KL et al:Human lipoprotein lipase complementary DNA sequence. Science 235:1638-1641, 1987
  pubmed

• 13) Sparkes RS et al:Human genes involved in lipolysis of plasma lipoproteins:Mapping of loci for lipoprotein lipase to 8p22 and hepatic lipase to 15q21. Genomics 1:138-144, 1987
  pubmed

• 14) Kirchgessner TG et al:organization of the human lipoprotein lipase gene and evolution of the lipase gene family. Proc Natl Acad Sci USA 86:9647-9651, 1989
  pubmed

• 15) 高木敦子, 池田康行:リポ蛋白リパーゼ (LPL). 広範囲 血液・尿化学検査, 免疫学的検査(2), 日本臨床, 東京, 1999, p62-68

• 16) Takagi A et al:Molecular studies on primary lipoprotein lipase (LPL) deficiency. one base deletion (G916) in exon 50f LPL gene causes no detectable LPL protein due to the absence of LPL mRNA transcript. J Clin Invest 89:581-591, 1992

• 17) Fisher RM, Humphries SE, Talmud PJ:Common variation in the lipoprotein lipase gene:effects on plasma lipids and risk of atherosclerosis. Atherosclerosis 135:145-159, 1997
  pubmed

• 18) 池田康行ほか:高トリグリセライド血症をどう考えるか(2)リポ蛋白リパーゼ. Progress in Medicine 15:2343-2357, 1995

• 19) 堤 善多ほか:低リポ蛋白リパーゼ群でのアルコールによる内因性高トリグリセライド血症の発症. -禁酒による正脂血化-. 日本消化器病学会誌 92:951-959, 1995

• 20) Ikeda Y et al:Physiological role of human hepatic triglyceride lipase (HTGL):HTGL regulates the multiple lipoprotein metabolism of IDL, LDL, and HDL2. Multiple Risk Factors in Cardiovascular Disease (Yamamoto A ed) , Churchill Livingstone Japan, Tokyo, 1994, pp181-186

• 21) Breckemidge WC et al:Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis 45:161-179, 1982

• 22) Carlson LA et al:Deficiency of hapatic lipase activity in postheparin plasma in farnilial hypercholesterolemia. Act Med Scand 219:435-447, 1986

• 23) Auwerx JH et al:Coexistence of abnormalities of hapatic lipase and lipoprotein lipase in a large family. Am J Hum Gener 46:470-477, 1990

• 24) Knundsen P et al:A compound heterozygote for hepatic lipase gene mutations Leu334→ Phe and Thr383→Met:correlation between hapatic lipase activity and phenotypic expression. J Lipid Res 37:825-834, 1996

• 25) 池田康行ほか:高トリグリセライド血症. Molecular Medicine 31:518-526, 1994

• 26) Lambert G et al:Hepatic lipase deficiency decreases the selective uptake of HDL-cholesterol esters in vivo. J Lipid Res 41:667-672, 2000
  pubmed

• 27) Hegele RA et al:Hepatic lipase deficiency:Clinical, biochemical, and molecular genetic characteristics. Arteriosclerosis and thrombosis 13:720-728, 1993
  pubmed

• 28) Martin GA et al:Isolation and cDNA sequence of human postheparin plasma hepatic triglyceride lipase. J Biol Chem 263:10907-10914, 1988
  pubmed

• 29) Ikeda Y et al:Mechanism of the production of small dense LDL(sLDL) in hypertriglyceridemia. In Atherosclerosis XI Proceedings of the 11th International Symposioum on Atheroscrelosis, 1998, pp777-788

• 30) Tahvanainen E et al:Association of variation in hepatic lipase activity with promoter variation in the hapatic lipase gene. J Clin Ihvest 101:956-960, 1998

• 31) 朝倉由加利ほか:ヒト肝性トリグリセリドリパーゼ (HTGL)生理作用の解明-甲状腺機能低下症治療前後のHTGLとリポ蛋白組成の検討. 動脈硬化 22:179-186, 1994

14 ◎ アルコールとIV型、V型高脂血症

P.201 掲載の参考文献

• 1) 中村治雄:アルコールと脂質代謝. 臨床成人病 18:2085, 1988

• 2) Clevidence BA et al:Effects of alcohol consumption on lipoproteins of premenopausal women. A controlled diet study. Arterioscler Thromb Vasc Biol 15:179-184, 1995
  pubmed

• 3) Nishiwaki M et al:Effects of alcohol on lipoprotein lipase, hepatic lipase, cholesteryl ester transfer protein, and lecithin:cholesterol acyltransferase in high-density lipoprotein cholesterol elevation. Atherosclerosis 111:99-109, 1994
  pubmed

• 4) Hojnacki JL et al:Alcohol delays clearance of lipoproteins from the circulation. Metabolism 41:1151-1153, 1992
  pubmed

• 5) Pownall HJ:Dietary ethanol is associated with reduced lipolysis of intestinally derived lipoproteins. J Lipid Res 35:2105-2113, 1994
  pubmed

• 6) Beblian P et al:Premature atherosclerosis in patients with familial chylomicronemia caused by mutation in the lipoprotein lipase gene. N Engl J Med 335:848-854, 1996

• 7) Kastelein JJ et al:Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group. Circulation 102:1629-1633, 2000

• 8) Vialettes B et al:Dietary fat clearance in type V hyperlipoproteinaemia secondary to a rare variant of human apolipoprotein E:the apolipoprotein E3(Arg 136--＞Ser) . Br J Nutr 83:615-622, 2000
  pubmed

15 ◎ 糖尿病と高トリグリセライド血症

P.211 掲載の参考文献

• 1) Wilson PW, Kannel NB, Anderson KM:Lipids, glucose intolerance and vascular disease:the Framingham Study. Monogr Atheroscler 13:1-11, 1985

• 2) Seltzer HS:A summary of criticisms of the findings and conclusions of the university Group Diabetes Program (UGDP) . Diabetes 21:976-979, 1972
  pubmed

• 3) 及川眞一, 小竹英俊:糖尿病患者における高トリグリセリド血症の動脈硬化への影響. Pharma Medica 15:113-118, 1997

• 4) Veniant MM, Zlot CH, Walzem RL et al:Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice. J Clin Invest 102:1559-1568, 1998
  pubmed

• 5) Bodzioch M et al:The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature Genetics 22:347-351, 1999
  pubmed

• 6) Brooks-Wilson A et al:Mutation in ABC1 in Tangier disease and familial high-density lipoprotein deficienc. Nature Genetics 22:336-345, 1999

• 7) Rust S et al:Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genetics 22:352-355, 1999
  pubmed

• 8) Hara H, Yokoyama S:Intraction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem 266:3080-3086, 1991

• 9) Sane T, Takinen MR:Dose familial hypertriglyceridemia predispose to NIDDM? Diabetes Care 16:1494-1501, 1993

• 10) unger RH:Lipotoxicity in the pathogenesis of obesity-dependent NIDDM; Genetic and clinical implications. Diabetes 44:863-871, 1995
  pubmed

• 11) Zhou YP, Berggren PO, Grill V:A fatty acid-induced decrease in pyruvate dehydrogenase activity is an important determinant of beta-cell dysfunction in the obese diabetic db/db mouse. Diabetes 45:580-586, 1996
  pubmed

• 12) Lee Y, Hirose H, Zhou YT et al:increased lipogenic capacity of the islets of obese rats:a role in the pathogenesis of NIDDM. Diabetes 46:408-416, 1997
  pubmed

• 13) Shimabukuro M, Zhou YT, Levi M et al:Fatty acid-induced beta cell apoptosis:a link between obesity and diabetes. Proc Natl Acad Sci USA 95:2498-2504, 1998
  pubmed

• 14) Frick MH, Elo O, Haapa K et al:Helsinki Heart Study:Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987
  pubmed

• 15) Ericsson C, Hamstem A, Nilsson J et al:Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347:849-853, 1996

• 16) Kaplinsky E:Bezafibrate Infarction Prevention Study (BIP Study):第20回欧州心臓学会会議(オーストリア. ウィーン), 1998

• 17) Steiner G:Lipid intervention trial in diabetes. Diabetes Care 238 (Suppl 2):B49, 2000

• 18) Elkeles RS et al:Cardiovascular outcome in type 2 diabetes/Adouble-blind placebo-controlled study of bezafibrate:the St. Mary's, Ealing, Northwick Park Diabetes Cardiovas-cular Disease Prevention(SENDCAP) study. Diabetes Care 21:641, 1998

• 19) Rubins HB, Robins SJ, Collins D et al:Gemfibrozil fbr the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999

16 ◎ 食後の高脂血症

P.226 掲載の参考文献

• 1) Zilversmit DG:A proposal linking atherosclerosis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ Res 33:633, 1973

• 2) Zilversmit DG:Postprandial hyperlipidemia and its relation to atherosclerosis. Latent Dyslipoproteinemias and Atherosclerosis(Genes JL ed) , Raven Press, New York, 1984, pp1-8

• 3) Zilversmit DG:Atherogenesis:Apostprandial phenomenon. Circulation 60:473-485, 1979

• 4) Karpe F:Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 246:341-355, 1999
  pubmed

• 5) 多田紀夫:レムナントリポ蛋白. The Lipid 7:38-41, 1996

• 6) Ross AC, Zilversmit DG:Chylomicron remnant cholesteryl esters as the major constituent of very low density lipoprotein in plasma of cholesterol fed rabbits. J Lipid Res 18:169-181, 1977

• 7) Melchior GW, Mahley RW, Buckhold DK:Chylomicron metabolism during dietary-induced hypercholesterolemia in dogs. Lipid Res 22:598-609, 1981
  pubmed

• 8) Goldstein JL, Ho YK, Brown MS et al:Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degeneration of hypercholesterolemic canine β-very low density lipoproteins. J Biol Chem 255:1839-1848, 1980

• 9) Mahley RW, Innerarity TL, Brown MS et al:Cholesteryl ester synthesis in macrophages:Stimulation byβ-very low density lipoproteins from cholesterol-fed animals of several species. J Lipid Res 21:970-980, 1980

• 10) Havel RJ:Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 5:102-109, 1995

• 11) Havel RJ:Remnant lipoproteins as therapeutic targets. Curr opin Lipidol 11:615-620, 2000
  pubmed

• 12) Karpe F, Steiner G, Uffelmann K et al:Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 106:83-97, 1994

• 13) Malmstrom R, Packard CJ, Watson TD et al:Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17:1454-1464, 1997
  pubmed

• 14) Boden G:Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997
  pubmed

• 15) Brunzell JD, Hazzard WR, Porte D et al:Evidence for a common, saturable, niglyceride removal mechanism for chylomicrons and very low density lipoproteins in manJ Clin Invest 52:1578-1585, 1973

• 16) Bjorkegren J, Packard CJ, Hamsten A et al:Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res 37:76-86, 1996
  pubmed

• 17) 多田紀夫, 池脇克則:食後高脂血症の診断法:脂肪負荷試験に伴う血清脂質とRLPの変化-リポ蛋白分画からの解析-. 動脈硬化 25:361-370, 1998

• 18) Cohn JS, Johnson EJ, Millar JS et al:Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl estersJ Lipid Res 34:2033-2040, 1993
  pubmed

• 20) Karpe F, Hellenius M-L, Hamsten A:Differences in posq) randial concentrations of very low density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary artery disease. Metabolism 48:301-307, 1999

• 21) 多田紀夫:レムナントリポ蛋白の動脈硬化発症メカニズム. 目でみる循環器病シリーズ 冠危険因子(松澤佑次編集), メジカルビュー社, 東京, 2000, pp36-41

• 22) Mamo JCL, Wheeler JR:Chylomicron or their remnants penetrate rabbit thoracic aorta as efficiently as do ammaller macromolecules, including low-density lipoprotein, high-density lipoprotein, and albumin. Coron Heart Dis 5:695-705, 1994

• 23) Rapp JH, Lespine A, Hamilton RL et al:Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterior Thromb 14:1767-1774, 1994

• 24) Ginsberg HN et al:Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol 15:1829-1838, 1995
  pubmed

• 25) Sharrett AR et al:Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. Arterioscler Thromb Vasc Biol 15:2122-2129, 1995
  pubmed

• 26) Weintraube MS, Grosskopf I, Rassin T et al:Clearance of chylomicron remnants in normolipidemic patients with coronary artery disease:case control study over three years. Br Med J 312:935-939, 1996

• 27) Gronholdt ML, Nordestgaard BG, Nielsen TG et al:Echoluscent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. Stroke 27:2166-2172, 1996

• 28) Meyer E, Westerveld HT, Ruyter-Meijstek FC et al:Abnomal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease:a case-control study. Atherosclerosis 124:221-235, 1996

• 29) Karpe F, de Faire u, Mercuri M et al:A magnitude of alimentary lipemia is related to intimamedia thickness of the common carotid artery in middle-aged men. Atherosclerosis. 141:307-314, 1998

• 30) 池脇克則:冠動脈硬化症における脂肪負荷後のリポ蛋白代謝の検討. 動脈硬化 18:887-895, 1990

• 31) 多田紀夫:レムナント様リポ蛋白. 臨床検査 40:1023-1029, 1996

• 32) Mahley RW:Atherogenic lipoproteins and coronary artery disease;concept derived from recent advances in cellular and molecular biology. Circulation 72:943-948, 1985

• 33) Tada N, Ikewaki K, Akutsu T et al:The effects of diacylglycerol loading orally on postpran-dial hyperlipidemia in man. Atherosclerosis 151:145, 2000

• 34) Murphy MC et al:Postprandial lipid and hormone responses to meals of varying fat contents:modulatory role of lipoprotein lipase? Eur J Clin Nutr 49:579-588, 1995

• 35) Fielding CJ et al:Effects of dietary cholesterol and fat saturation on plasma lipoproteins in an ethnically diverse population of healthy young men. J Clin Invest 95:611-618, 1995

• 36) Durlach V et al:Postprandial cholesteryl ester transfer and high density lipoprotein composi-tion in nomiotriglyceridemic non-insulin-dependent diabetic patients. Atherosclerosis 120:155-165, 1996

• 37) Cavallero E et al:Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postpran LpA-I particles. Arterioscler Thromb Vasc 15:2130-2135, 1995
  pubmed

• 38) 多田紀夫:食後高脂血症と高レムナント血症-脂肪負荷試験の意義-. 動脈硬化 27:319-325, 2000

• 39) Syvanme M, Hilden H, Taskinen M-R:Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary heart disease. J Lipid Res 35:15-26, 1994

• 40) Peacock RE et al:Common variation in the gene for apolipoprotein B modulates postprandial lipoprotein metabolism:a hypothesis generating study. Atherosclerosis 116:135-145, 1995
  pubmed

• 41) Bergeron N, Havel RJ:Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein ε 4allele. J Clin Invest 97:65-72, 1996

• 42) Reznik Y et al:Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin dependent diabetic patients:influence of apolipoprotein E polymorphism. Metabolism 45:63-71, 1996
  pubmed

• 43) Bergeron N, Havel RJ:Assessment of posq｝randial lipemia:nutritional influences. Curr Opin Lipidol 8:43-52, 1997

• 44) 多田紀夫:アポ蛋白-密度勾配電気泳動法-. 臨床検査 29:1416-1421, 1985

17 ◎ 女性ホルモンとトリグリセライド代謝、高脂血症

P.236 掲載の参考文献

• 1) 厚生省保険医療局疾病対策課:第4次循環器疾患基礎調査の概要, 1992

• 2) Grodstein F, Stampfer MJ, Colditz GA et al:Postmenopausal hormone therapy and mortality. N Engl J Med 336:1769-1775, 1997
  pubmed

• 3) Colvin PL, Auerbach BJ, Case LD et al:A dose-response relationship between sex hor none-induced change in hepatic triglyceride lipase and high-density lipoprotein in postmenopausal women. Metabolism 40:1052-1056, 1991

• 4) Ma PT, Yamamoto T, Goldstein JL et al:Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17 alpha ethinyl-estradiol. Proc Natl Acad Sci USA 83:792-796, 1986
  pubmed

• 5) Walsh BW, Schiff I, Rosner B et al:Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325:1196-1204, 1991
  pubmed

• 6) Wakatsuki A, Ikenoue N, Sagara Y:Effect of estrogen on the size of low-density lipoprotein particles in postmenopausal women. obstet Gynecol 90:22-25, 1997
  pubmed

• 7) Wakatsuki A, Okatani Y, Ikenoue N:Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type II a hyperchole-sterolemia. Atherosclerosis 150:103-111, 2000

• 8) Kuribayashi T, Okada M, Tanaka K et al:Eicosapentaenoic acid effect on hyperlipidemia in menopausal women in Japan. obstet Gynecol 96:521-528, 2000

• 9) Shlipak MG, Simon JA, Vitnghoff E et al:Estrogen and progestin, lipoprotein(a) , and the risk of recurrent coronary heart disease events after menopause. JAMA 284:1845-1852, 2000

• 10) 佐久間一郎:本邦閉経後女性へのホルモン補充療法における用法・用量と凝固・線溶系への影響. 高齢女性の健康増進のためのホルモン補充療法ガイドライン(大内 尉義編), メディカルレビュー社, 東京, 2001, pp240-242

• 11) Lobo RA, Bush T, Car BR et al:Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fenility and Sterility 76:13-24, 2001

• 12) Sanada M, Nakagawa H, Kodama I:The effect of hormone replacement therapy on metabolism of lipoprotein remnants in postmenopausal women. Maturitas 34:75-82, 2000
  pubmed

• 13) Tchemof A, Calles-Escandon J, Sites CK et al:Menopause, central body fatness, and insulin resistance:effects of hormone-replacement therapy. Coron Artery Dis 9:503-511, 1998
  pubmed

• 14) Tchemof A, Peohlman ET, Despres JP:Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes Metab 26:12-20, 2000

• 15) Kimmerle R, Heinemann L, Heise T et al:influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 6:36-42, 1999
  pubmed

• 16) Brussaard HE, Gevers-Leuven JA, Kluft C et al:Effect of 17 β-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus. Arterioscl Thromb Vascl Biol 17:324-330, 1997

• 17) Goldsland IF:The influence of female sex steroids on glucose metabolism and insulin action. Intern Med Supp1738:1-60, 1996

• 18) 高齢女性の健康増進のためのホルモン補充療法ガイドライン(大内尉義編), メディカルレビュー社, 東京, 2001

18 ◎ 高トリグリセライド血症の治療

P.257 掲載の参考文献

• 1) Havel RJ:Benefits of fibrate(imgs in coronary heart disease patients with normal cholesterol levels. Circulation 96:2113-2114, 1997

• 2) Austin MA, Hokanson JE, Edwards KL:Hypemhglyceridemia as a cardiovascular risk factor. Am J Cardiol 81:7B-12B, 1998
  pubmed

• 3) Frick MH, Elo O, Haapa K et al:Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987
  pubmed

• 4) Rubins HB, Robins SJ, Collins D et al:Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol intervention Trial Study Group. N Engl J Med 341:410-418, 1999

• 5) Ruotolo G, Ericsson CG, Tettamanti C et al:Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclero sis Intervention Tria1(BECAIT) . J Am Coll Cardiol 32:1648-1656, 1998

• 6) Goldbourt U, Brunner D, Behar S et al:Baseline characteristics of patients participating in the Bezafibrate infarction Prevention (BIP) Study. Eur Heart J 19 (Suppl H):H42-H47, 1998

• 7) Elkeles RS, Diamond JR, Poulter C et al:Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate:the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 21:641-648, 1998

P.269 掲載の参考文献

• 1) 垂井清一郎:厚生省特定疾患原発性高脂血症調査研究班昭和62年度報告書, 1987

• 2) Hokanson JE, Austin MA:Plasma triglyceride level is a risk factor for cardiovasculardisease independent of high-density lipoprotein cholesterol level:a meta-analysis ofpopulation-based prospective stu［dies. J Cardiovasc Risk 3:213-219, 1996

• 3) Nakamura T, Tokunaga K, Shimomura I et al:Contribution of visceral fat accumulation tothe development of coronary artery disease in non-obese men. Atherosclerosis 107:239-246, 1994

• 4) Pedersen TR, olsson AG, Faergeman o et al:Lipoprotein changes and reduction in theincidence of major coronary heart disease events in the Scandinavian Simvastatin SurvivalStudy (4S) . Circulation 97:1453-1460, 1998

• 5) Ericsson CG, Hamsten A, Nilsson J et al:Angiographic assessment of effects of bezafibrateon progression of coronary artery disease in young male postinfarction patients. Lancet 347:849-853, 1996
  pubmed

• 6) The BIP study group:Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease-The bezafibrate infarction prevention (BIP) study. Circulation 102:21-27, 2000

19 ◎ IDL、レムナント測定法

P.274 掲載の参考文献

• 1) Hokanson JE, Austin MA:Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level:a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213-219, 1996

• 2) Zilversmit DB:Atherogenesis:a postprandial phenomenon. Circulation 60:473-485, 1979
  pubmed

• 3) Nakajima K, Saito T, Tamura A et al:Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 223:53-71, 1993
  pubmed

• 4) Doi H, Kugiyama K, ohgushi M et al:Remnants of chylomicron and very low density lipoprotein impair endotheuum-dependent vasorelaxation. Atherosclerosis 137:341-349, 1998
  pubmed

• 5) Doi H, Kugiyama K, Oka H et al:Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 102:670-676, 2000
  pubmed

• 6) Kugiyama K, Doi H, Motoyama T et al:Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 97:2519-2526, 1998
  pubmed

• 7) Masuoka H, Kamei S, Ozaki M et al:Predictive value of remnant-like particle cholesterol as an indicator of coronary artery stenosis in patients with normal serum triglyceride levels. Intern Med 39:540-546, 2000
  pubmed

• 8) Kugiyama K, Doi H, Takazoe K et al:Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99:2858-2860, 1999
  pubmed

• 9) McNamara JR, Shah PK, Nakajima K et al:Remnt-like particle (RLP) cholesterol is independent cardiovascular disease risk factor in women:results from the Framingham Heart Study. Atherosclerosis 154:229-236, 2001
  pubmed

• 10) Karpe F, Boquist S, Tang R et al:Remnant lipoproteins are related to intimamedia thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 42:17-21, 2001
  pubmed

P.281 掲載の参考文献

• 1) Toshimi K et al:Lipoprotein Analysis using Agarose Gel Electrophoresis and Differential Staining of Lipids. J Atheroscler Thromb 8(1):7-13, 2001

• 2) 貴堂としみほか:アガロース電気泳動法によるリポ蛋白分析の臨床応用. The Lipid 9:487-494, 1998
  Medical*Online

• 3) 浦田武義:脂質分別定量法(酵素法). 臨床検査 29(11):1344-1352, 1985

• 4) 中里 功ほか:脂質電気泳動に用いる血清検体の保存方法について. 第15回サンプリング研究会講演抄録, 2001, p35

• 5) 大井絹枝ほか:血清コレステロール分画・トリグリセライド分画同時測定法. 検査と技術 29(8):973-979, 2001

• 6) Daniel LS, Michael CP:Quantitative measurement of lipoprotein surface charge by agarose gel electrophoresis. Journal Lipid Res 33:123-130, 1992

• 7) Michael La Belle, Patricia JB, Ronald MK:Charge properties of low density lipoprotein subclasses. Journal Lipid Res 38:690-700, 1997

• 8) 大井絹枝ほか:血清コレステロール分画トリグリセライド分画同時測定によるLDL分画質的異常の検討. 生物物理化学 45:83-88, 2001

• 9) 蔵田英明ほか:糖尿病におけるリポ蛋白異常の臨床的意義. 2001動脈硬化学会シンポジウム, p122

• 10) 橋本陽子ほか:糖尿病患者群を対象としたコレトリコンボにおけるLDL変性度数の検討. JJCLA 25(4):359, 2000

P.286 掲載の参考文献

• 1) Hara I, okazaki M:High-performance liquid chromatography of serum lipoprotein. Methods Enzymol 129:57-78, 1986
  pubmed

• 2) Okazaki M, Usui S, Hosaki S:Analysis of plasma lipoproteins by gel permeation chromatography. Handbook of Lipoprotein Testing, 2nd Edition (Rifai N, Warnick GR, Dominiczak MH ed) , AACC Press, Washington DC, 2000, pp647-669

• 3) Usui S, Jitsukata K, Kazama H et al:Simultaneous analysis of serum lipoprotein cholesterol and triglycerides by a HPLC method. Clin Chem 46 (S6):A103, 2000

• 4) Okazaki M, Usui S, Tada N et al:Relation between RLP-triglyceride to RLP-cholesterol ratio and particle size distribution in RLP-cholesterol profiles by HPLC. Clin Chim Acta 296:135-149, 2000
  pubmed